Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

Phase 4

Completed

• Conditions: Major Depressive Disorder
• Interventions: Drug: Desvenlafaxine; Drug: Vortioxetine

• Registration Number: NCT04448431
• Lead Sponsor: H. Lundbeck A/S

Brief Summary

The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit

Detailed Description

The study will consist of a screening period of up to 14 days before the Baseline Visit, followed by an 8-week Treatment Period with vortioxetine or desvenlafaxine. A Safety Follow-up Visit will be performed approximately 4 weeks after the Primary Outcome/Withdrawal Visit.

At Baseline, patients will be equally randomised (1:1) to 1 of the 2 treatment groups for an 8-week, double-blind Treatment Period.

Study Timeline

• Study Start: 2020-06-18
• Study First Submitted: 2020-06-23
• Study First Submitted QC: 2020-06-23
• Study First Posted: 2020-06-25
• Primary Completion: 2022-01-06
• Status Verified: 2022-02
• Study Completion: 2022-02-04
• Last Update Submitted: 2022-02-11
• Last Update Posted: 2022-02-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 605

Inclusion Criteria

• The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to DSM-5®. The current MDE must be confirmed using the Mini International Neuropsychiatric Interview (MINI).
• The patient has a MADRS total score ≥24 at screening and baseline.
• The patient has had the current MDE for ≥3 months and < 12 months.
• The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE with a partial response and is a candidate for a switch in the investigator's opinion.
• The patient wants to switch antidepressant treatment.

Exclusion Criteria

• The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.

Other in- and exclusion criteria may apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Desvenlafaxine	Desvenlafaxine	8 weeks treatment
Vortioxetine	Vortioxetine	8 weeks treatment

Primary Outcome Measures

Name	Time	Method
Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score	From baseline to Week 8	The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

Secondary Outcome Measures

Name	Time	Method
Remission (defined as a MADRS total score =<10)	At Week 8	The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.
Change in Digital Symbol Substitution Test (DSST) total score	From baseline to Week 8	DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\< normal functioning) to 133 (\> normal functioning).
Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) total score	From baseline to Week 8	The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)
Change in Q-LES-Q work subscale	From baseline to Week 8	The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)
Change in Q-LES-Q school/course subscale	From baseline to Week 8	The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)
Change in Q-LES-Q leisure time activities subscale	From baseline to Week 8	The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)
Change in MADRS anhedonia factor score	From baseline to Week 8	(based on items 1(apparent sadness),2 (reported sadness),6 (concentration difficulties),7 (lassitude),8 (inability to feel))
Clinical Global Impression Scale- Global Improvement (CGI-I) score	at Day 7,28,56	The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse)
Response (defined as a => 50% decrease from baseline in MADRS total score)	At Week 8	The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.
The proportion number of Hard Choice/number of High Reward trials and number of Low choice/number of Low Reward trials when performing the Effort- Expenditure for Rewards Task (EEfRT)	From baseline to Week 8	The EEfRT is a computerized task which measures reward motivation in which participants are presented with a series of repeated trials during which they choose between performing a ''hard-task'' or an ''easy-task'' in order to earn varying amounts of monetary rewards.
Change in Clinical Global Impression - Severity of Illness (CGI-S) score	from baseline to Week 8	The CGI-S scale measures the severity of psychiatric symptoms on a 7-point scale from 1-7. The scores indicated the following: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. The score ranged from 1-7, where 1 indicated absence of symptoms and higher score indicated greater severity of symptoms.
Change in Functioning Assessment Short Test (FAST) total score	From baseline to Week 8	The FAST is a valid and reliable instrument, easy to apply which requires a short period of time to administer. Evaluates functioning taking into account the last 15 days. It was developed for the clinical evaluation of the main difficulties presented by psychiatric patients, and has been validated in several languages for patients with bipolar disorder. The FAST scale consists of 24 items which allow the assessment of six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time
Change in FAST sub-domain scores	From baseline to Week 8	The FAST is a clinician-rated scale designed to assess difficulty in functioning. The FAST consists of 24 items in 6 specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, leisure time. Each item is rated on a 4-point scale from 0 (no difficulty) to 3 (severe difficulty). The items are summed to yield a total score ranging from 0 to 72 with higher scores reflecting more serious difficulties.
Change in Q-LES-Q household duties subscale	From baseline to Week 8	The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)
Change in Q-LES-Q social relations subscale	From baseline to Week 8	The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)

Trial Locations

Locations (80)

Clinica Privada Banfield; 🇦🇷 Banfield, Buenos Aires, Argentina

Cenydet-Centro Neurobiologico Y De Estres Traumatico-Biopsychomedical Research Group Srl; 🇦🇷 Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

Fundacion para el Estudio y Tratamiento de las enfermedades mentales FETEM; 🇦🇷 Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

INAPsi (Instituto Nacional de Psicopatologia); 🇦🇷 Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Clinica Privada De Salud Mental Santa Teresa De Avila; 🇦🇷 La Plata, Buenos Aires, Argentina

Instituto De Neurociencias San Agustin SA; 🇦🇷 La Plata, Buenos Aires, Argentina

Sanatorio Prof. Leon S. Morra S.A.; 🇦🇷 Cordoba, Providencia De Cordo, Argentina

CIAP (Centro de Investigacion y Asistencia en Psiquiatria); 🇦🇷 Rosario, Santa Fe, Argentina

CINME (Centro de Investigaciones Metabolicas de Buenos Aires); 🇦🇷 Ciudad Autonoma De Buenos Aires, Argentina

CEN (Centro Especializado Neurociencias); 🇦🇷 Cordoba, Argentina

Scroll for more (70 remaining)